1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Spinal Muscular Atrophy: Forecast in Asia-Pacific Markets to 2028

Spinal Muscular Atrophy: Forecast in Asia-Pacific Markets to 2028

  • November 2019
  • 104 pages
  • ID: 5816846
  • Format: PDF
  • GlobalData

Summary

Table of Contents

Search Inside

Spinal Muscular Atrophy: Forecast in Asia-Pacific Markets to 2028

Summary
Spinal Muscular Atrophy (SMA) is a rare genetic neurodegenerative disease that primarily affects children.It is characterized by loss of spinal motor neurons, which are specialized cells that control muscle movement.

The Spinal Muscular Atrophy (SMA) market across the five growth markets (5GM) Australia, China, India, Japan and South Korea in the Asia-Pacific (APAC) region is anticipated to grow at a compound annual growth rate of 23.3% from US$308.6m in 2018 to US$2.5bn in 2028. Increased uptake of the first disease-modifying Spinal Muscular Atrophy (SMA) therapies will drive the robust growth during the outlook period.

Biogen’s antisense therapy Spinraza (nusinersen) was first approved for the treatment of Spinal Muscular Atrophy (SMA) in Japan in June 2017 and has since been approved in Australia, South Korea and China. The approval of this drug is revolutionizing the management of the disease, with clinically meaningful improvements in motor function, achievement of milestones and survival observed for the first time in children with Spinal Muscular Atrophy (SMA).

Spinraza accounted for the vast majority of sales across the (5GM) Australia, China, India, Japan and South Korea in 2018 and sales are projected to remain strong throughout the early-to-mid forecast period (2018-2023). However, Spinraza is projected to lose its monopoly in the mid-to-late forecast period (2023-2028), as pipeline products launching from 2020 onwards are expected to capture significant market share.

Key opinion leaders express excitement regarding the potential of the late-stage pipeline to expand access to therapy and address key unmet needs.In particular, Novartis’ gene therapy Zolgensma (onasemnogene abeparvovec-xioi) represents a potentially transformative treatment option, as it is administered by a one-time intravenous infusion.

This represents a strong differentiating factor from Spinraza, which requires intrathecal administration multiple times per year.

Zolgensma, which has already received approval in the US, is expected to emerge as the market leader in the APAC region by 2028 with sales of US$1.3bn across the (5GM) Australia, China, India, Japan and South Korea. Additionally, the launch of Roche’s risdiplam, an SMN2 splicing modifier, is also eagerly anticipated owing to the drug’s convenient oral administration route.

Although Spinraza’s approval represented a major breakthrough in the field, there is still an unmet need for additional therapies that employ novel mechanisms of action and administration routes, which can translate into improvements in efficacy, accessibility, ease of use, and patient compliance.

The latest research report “Spinal Muscular Atrophy: Forecast in Asia-Pacific Markets to 2028” helps in answering the following question with regards to Spinal Muscular Atrophy (SMA) and its therapeutic market in Asia Pacific.

- How Spinal Muscular Atrophy (SMA) is currently managed and does this vary by subtype?
- To what extent will the launch of pipeline products over the forecast period fulfill the unmet needs in the market?
- How will the launch of pipeline products impact Spinraza?
- How will growth vary by market?

Scope
- Overview of SMA, including epidemiology, etiology, pathophysiology, classification, diagnosis, and disease management.
- Market Data including annualized SMA therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in fours patient segments (Type 1, 2, 3, and 4) forecast from 2018 to 2028.
- Key topics covered include unmet needs and opportunity assessment, R&D strategies and clinical trial design.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for SMA therapy. The most promising candidates in Phase II and III development are profiled.
- Analysis of the current and future market competition in the SMA therapeutics market: Insightful review of the industry drivers and barriers and in-depth analysis of trends within each of the 5GM.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies most active within the SMA APAC landscape.
- Develop business strategies by understanding the trends shaping and driving the SMA APAC market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the SMA APAC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global TROP2 Antibody Market & Clinical Trials Insight 2026

  • $ 2400
  • November 2021
  • 90 pages

Global TROP2 Antibody Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights: • Research Methodology • Global & Regional Market Analysis • Global TROP2 Antibody Market Opportunity ...

  • World
  • Pharmaceutical
  • Lung Cancer
  • Industry analysis
  • Drug Approval

ref:plp2019

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on